Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis (NCT04915352) | Clinical Trial Compass
TerminatedPhase 4
Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
Stopped: The study is terminated because the product (nasal provocation test) is out of stock.
France8 participantsStarted 2022-03-07
Plain-language summary
The aim of this clinical trial is to compare the positive predictive value of the combination rapid nasal provocation test (RNTP) + skin tests (TC) + specific immunoglobulins E (IgEs) to the combination of TC + IgEs (strategy currently used in clinical practice) concerning the efficacy of treatment with Allergen immunotherapy (ITA) at 1 year, in patients with symptoms suggesting allergic rhinitis to house dust mites.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient over 18 years old,
* Patient with persistent mild to severe or moderate to severe intermittent rhinitis according to ARIA criteria, suspicion of allergic rhinitis to dust mites, and a positive skin test for mites and / or a positive mite specific IgE assay
* Patient having signed a free and informed consent
Exclusion Criteria:
* Pregnant or breastfeeding women
* Patients under guardianship or curatorship
* Patients under legal protection
* Patients not affiliated to a social security scheme
* Contraindications to performing a RNPT
* Active ENT or respiratory infections.
* Allergy in acute phase
* History of anaphylaxis due to the allergen involved.
* Unstabilized asthma and other obstructive pathologies.
* Severe general illnesses in evolution.
* Hypersensitivity to one of the components of the product
* Simultaneous treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors,
* Presence of an excessive degree of sensitization (e.g. history, excessive skin reactions),
* Contraindications to immunotherapy:
* Asthma (uncontrolled) or severe \[FEV \< 70% of the theorical value (after appropriate drug treatment) at the beginning of the treatment\].
* Severe asthma exacerbation in the last 3 months
* Active autoimmune diseases
* Malignant tumors
* Pregnancy (initiation of venereal disease)
* AIDS
* Treatment with beta-blockers, including eye drops
What they're measuring
1
The negative predictive value calculated with the efficacy of ITA at 1 year